Overview

An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension

Status:
Completed
Trial end date:
2021-08-12
Target enrollment:
0
Participant gender:
All
Summary
This study is an international, multi-center, open-label study designed to provide oral treprostinil (UT-15C) to eligible subjects with pulmonary arterial hypertension who have completed the TDE-PH-310 study. The purpose of this study is to assess the long-term safety of UT-15C and to assess the effects of long-term treatment with UT-15C on exercise capacity.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
United Therapeutics
Treatments:
Treprostinil
Criteria
Inclusion Criteria:

- Participated in United Therapeutics Study TDE-PH-310

Exclusion Criteria:

- Premature discontinuation of United Therapeutics Study TDE-PH-310 due to reasons other
than clinical worsening